<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308358">
  <stage>Registered</stage>
  <submitdate>20/08/2009</submitdate>
  <approvaldate>26/08/2009</approvaldate>
  <actrnumber>ACTRN12609000739213</actrnumber>
  <trial_identification>
    <studytitle>Spinal Modulation Neurostimulator System in the Treatment of Chronic Pain</studytitle>
    <scientifictitle>Does the Spinal Modulation Neurostimulator System provide safe and efficacious pain relief in people with chronic pain?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study uses an invasive neurostimulation device that is used for up to 24 hours per day. Duration of treatment in this study is 3-10 days. Part of the device is implanted in the patient and the device is controlled with a hand held remote. The amount of therapy used throughout the day is patient controlled.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as assessed by complications and adverse events. Adverse events can include increasing pain, numbness and events associated with epidural needle access. These will be assessed daily via interview and questionnaires.</outcome>
      <timepoint>Daily assessments for 3-10 days following treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain Relief as assessed by visual analog scale</outcome>
      <timepoint>Daily assessments for 3-10 days following treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Chronic pain
2. Failed conservative treatments</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Primarily axial back pain</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Five Corners Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Five Corners Pty Ltd
13/76 Reserve Road
ARTARMON  NSW   2064</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Spinal Modulation</fundingname>
      <fundingaddress>1135 O'Brien Drive
Menlo Park, CA 94025</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the current study is to determine the safety and efficacy of a neuromodulation therapy in the treatment of chronic pain. We hypothesize that this study will demonstrate safe delivery of therapy which will result in significant pain relief.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeff Kramer, PhD</name>
      <address>Spinal Modulation
1135 O'Brien Dr.
Menlo Park, CA 94025</address>
      <phone>+1 650-543-6836</phone>
      <fax />
      <email>jeff@spinalmodulation.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeff Kramer, PhD</name>
      <address>Spinal Modulation
1135 O'Brien Dr.
Menlo Park, CA 94025</address>
      <phone>+1 650-543-6836</phone>
      <fax />
      <email>jeff@spinalmodulation.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeff Kramer, PhD</name>
      <address>Spinal Modulation
1135 O'Brien Dr.
Menlo Park, CA 94025</address>
      <phone />
      <fax />
      <email />
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>